Gynecologic Oncologist @Moffittnews. Assistant PD @MoffittGYNONC. Targeted Therapy Explorer. Trained @MDAndersonnews. Views mine.
Joined March 2019
- Tweets 496
- Following 861
- Followers 1,173
- Likes 1,850
138 Photos and videos
Great #MedEd training day at @CAMLSTAMPA multiD #oncology lab @MoffittNews- @MoffittGYNONC @MoffittGUOnc, SurgOnc & CRS. Kudos M Hoffman @LoganZemp @ErinGeorgeMD, S Dineen, S Gilbert, S Felder, M Hayes, A. Sinammon, M Shahzad, H Chon, @biancatng1, @LindseyNguyMD @baxter_intl
1
11
352
Dr.Monica Avila retweeted
Jun 13
It was a fantastic surgical simulation opportunity with @MoffittGUOnc fellows, faculty members and other specialists from @MoffittNews today. The skills we honed will undoubtedly make a huge difference in the lives of many future patients.
1
6
377
Dr.Monica Avila retweeted
Jun 11
@MoffittNews was the No. 1 brand in total engagements at #ASCO26 🎉🚀
Thanks @karenluMD and @PatrickHwuMD for your inspiring leadership! And huge thanks to the media team for their hard work on this coverage!
#teamwork
5
17
524
Jun 11
Congratulations @LindseyNguyMD on graduating from @MoffittNews @MoffittGYNONC! 🎊💫 You will be deeply missed and your razor sharp clinical acumen 🪄will serve you well! @UTHealthHouston is so lucky to have you!
@karenluMD @PatrickHwuMD @ErinGeorgeMD
2
20
1,822
Dr.Monica Avila retweeted
11
25
1,992
Dr.Monica Avila retweeted
At #ASCO26, Karen Lu, MD (@karenluMD), joins @PatrickHwuMD to discuss Moffitt’s strong presence at the annual meeting and the innovations driving the future of cancer care.
From advances in targeted therapies and immunotherapy to leadership in digital pathology and rare cancer diagnosis, they highlight how Moffitt continues to help shape the next generation of oncology breakthroughs. #MoffittASCO26
12
19
1,266
Dr.Monica Avila retweeted
6
8
446
Dr.Monica Avila retweeted
From #ASCO26, Mihaela Druta, MD (@MihaelaDruta), highlights a study she co-authored evaluating afamitresgene autoleucel (afami-cel), a MAGE-A4-targeted T-cell therapy, in advanced synovial sarcoma.
Pooled trial data showed meaningful responses, pointing to the potential of engineered T-cell therapies for patients with this rare and challenging disease. #MoffittASCO26
9
14
898
Dr.Monica Avila retweeted
Live from #ASCO26: Kedar Kirtane, MD (@DrKedarKirtane), discusses emerging cell therapies in head and neck cancer and advances helping shape the future of treatment.
Key takeaways:
• Head and neck cancers are uniquely positions to respond to immune modulation.
• TILs, TCRs, and CAR-T represent the most common cell therapy approaches—thus far with modest results.
• New advancements in these arenas will hopefully improve overall survival and quality of life.
#MoffittASCO26
6
10
620
May 31
Great time at 2nd poster @ASCO w/ @A2Bio68125: safety & efficacy of logic gated CAR-T (MSLN agonist) in all solids of HLA02 & LOH. Notable CR in lung & SD in 8/13 pts treated thus far. Next phase showcases armored 🗡️ CAR-T with tethered IL-12 @MoffittNews #ASCO26
@DrKedarKirtane
5
16
803
Dr.Monica Avila retweeted
While at #ASCO26, Monica Avila, MD (@MAvilaMD), stopped by the #MoffittASCO26 booth to discuss early findings from the EVEREST-2 trial, including safety, efficacy and encouraging signs of clinical activity as researchers continue evaluating this CAR-T cell therapy approach.
1
8
17
715
May 31
Lovely night @PatrickHwuMD and @karenluMD at the @ASCO @MoffittNews reception @BlackstoneHotel !!!
Kudos to #MoffittASCO26 media/event crew making all the #science 💫 capture 📸 possible: @PatCarragher @julia_andresen @MadisonSkipp19 and many more! #ASCO26
5
17
885
Dr.Monica Avila retweeted
We caught up with Karen Lu, MD (@karenluMD), and Monica Avila, MD (@MAvilaMD), at the #MoffittASCO26 booth to discuss exciting developments in gynecologic cancers, from encouraging survival data in uterine cancer to emerging targeted therapies and antibody-drug conjugates that may help shape future treatment options for patients. #ASCO26
6
10
577
May 30
Great Day @MoffittNews at the #MeettheExpert booth, running into lovely colleagues and collaborators alike @A2Bio68125 at the poster sessions @ASCO!
#ASCO26 #MoffittASCO26
@jahow514 @MihaelaDruta
3
16
979
Dr.Monica Avila retweeted
May 30
While at #ASCO26, I spoke with Dr. Monica Avila (@MAvilaMD), gynecologic oncologist @Moffittnews, about her work advancing care for patients with gynecologic malignancies.
Dr. Avila specializes in complex surgical approaches, including minimally invasive techniques, and has a strong interest in HPV-driven malignancies. #ASCO26 #MoffittASCO26
7
18
1,151
May 30
Temab-A basket trial targeting C-MET ADC with TOPO1 payload. Cohorts included PROC including 8 clear cell pts with ORR of 44% with CBR 85% (100% in clear cell!) regardless of cMET expression. #ASCO26 #MoffittASCO26
@MoffittNews
1
11
702
May 30
TUB-040 ph I trial NAPi2b ADC heavily pretreated (median 4 priors &most seeing prior Bev/parp)showed impressive waterfall plot!!! 🤩 ORR of 61% regardless of low/high expression with 11mo median PFS with DOR not reached w/ very favorable AE #ASCO26 #MoffittASCO26 @MoffittNews
1
14
655
May 30
BAT8006 phase Ib/II trial of FR alpha ADC with anti-PD1 in recurrent or progressive #endometrial cancer and PROC. ORR 40% and CBR of 80% in #endometrial population not selected for FR alpha. #ASCO26 #MoffittASCO26 @MoffittNews
2
12
907
May 30
PRESERVE004 pH II trial OS data of anti CTLA-4 Gotisobart in a PR #ovarian cancer with median prior 4 lines and up to 10 priors. 21% ORR with DCR 45% and median DOR of 21months!!!! Median OS of 18months!!
#ASCO26 #MoffittASCO26 @MoffittNews
2
3
20
2,353
May 30
TEDOVA vaccine trial in PS #ovarian cancer targeting OSE2101 tumor antĂgens to increase binding to HLA02, T cell response. Pts had response prior platinum 1:1:2 to placebo,vaccine, vaccine IO. 80 saw prior Bev/PARP PFS benefit 47% reduction #ASCO26 #MoffittASCO26 @MoffittNews
2
12
570